Mirzayans R, Middlestadt M V, Paterson M C
Molecular Genetics and Carcinogenesis Laboratory, Cross Cancer Institute, Edmonton, Alberta, Canada.
Carcinogenesis. 1992 Jul;13(7):1185-90. doi: 10.1093/carcin/13.7.1185.
A non-transformed human fibroblast strain, GM11, established from the skin of a therapeutically aborted fetus, has been reported to exhibit the Mer- phenotype, i.e. inability to support the growth of adenovirus 5 damaged with 1-methyl-3-nitro-1-nitrosoguanidine. In the present study we determined (i) loss of colony-forming ability and frequency of mutants resistant to 6-thioguanine (6TG) on exposure to the SN1 alkylating agent methylnitrosourea (MNU) and (ii) amount of O6-methylguanine-DNA methyltransferase (MGMT), the protein responsible for repairing O6-methylguanine (O6mG) produced by MNU, in GM11 cells compared to GM10, a Mer+ human fetal fibroblast strain. Irrespective of in vitro culture age, GM10 cells responded normally to the cytotoxic action of the alkylating agent, i.e. their clonogenic survival curves exhibited a shoulder at low MNU concentrations (less than or equal to 0.4 mM) and a D10 (dose reducing survival to 10%) of approximately 1.4 mM. By contrast, no shoulder was observed on the survival curves of GM11 cells and their D10 values decreased from approximately 0.6 mM at passage 4 to 0.1 mM at passage 27. In GM10 (Mer+) cells, unlike the biphasic dose response seen for cell killing, the frequency of 6TG-resistant mutants increased as a linear function of chemical concentration delivered (range 0.05-1.2 mM); the induced mutation frequency in these cells (passage 16-20) was equal to 220 x 10(-6)/mM MNU, a yield some 5-fold greater than that reported by others for non-fetal human fibroblasts. GM11 cells proved to be only approximately 1.5 times more mutable by MNU than GM10 cells at late passage, and the susceptibility of the former strain to MNU-induced mutations did not change significantly as a function of culture age (i.e. 316 x 10(-6) and 326 x 10(-6) mutants/mM MNU at passages 4 and 16-20 respectively). The GM10 strain contained approximately 75,000 MGMT molecules/cell at all passages (4-20) examined, whereas the GM11 strain harbored deficient amounts of the protein (approximately 22,500 molecules/cell) at the lowest passage available (4), and this residual activity decreased precipituously to undetectable amounts by passage 16. Together, these data demonstrate that in the two human fetal strains examined the constitutive level of cellular MGMT activity correlates much better with resistance to reproductive inactivation than with mutagenesis by MNU, implying that inefficient repair of O6meG lesions impacts more severely on cell lethality than on mutation induction in at least some biological systems.
据报道,从治疗性流产胎儿皮肤中分离出的非转化人成纤维细胞系GM11表现出Mer-表型,即无法支持经1-甲基-3-硝基-1-亚硝基胍处理而受损的腺病毒5的生长。在本研究中,我们测定了:(i) 在暴露于SN1烷基化剂甲基亚硝基脲(MNU)时,GM11细胞集落形成能力的丧失以及对6-硫代鸟嘌呤(6TG)耐药的突变体频率;(ii) 与Mer+人胎儿成纤维细胞系GM10相比,GM11细胞中O6-甲基鸟嘌呤-DNA甲基转移酶(MGMT)的含量,MGMT是负责修复由MNU产生的O6-甲基鸟嘌呤(O6mG)的蛋白质。无论体外培养代数如何,GM10细胞对烷基化剂的细胞毒性作用反应正常,即它们的克隆存活曲线在低MNU浓度(小于或等于0.4 mM)时出现一个坪区,D10(使存活率降低至10%的剂量)约为1.4 mM。相比之下,GM11细胞的存活曲线上未观察到坪区,其D10值从第4代时的约0.6 mM降至第27代时的0.1 mM。在GM10(Mer+)细胞中,与细胞杀伤所呈现的双相剂量反应不同,对6TG耐药的突变体频率随所给予的化学物质浓度(范围为0.05 - 1.2 mM)呈线性增加;这些细胞(第16 - 20代)中的诱导突变频率等于220×10⁻⁶/mM MNU,这一产量比其他报道的非胎儿人成纤维细胞约高5倍。在传代后期,GM11细胞经MNU诱导的突变率仅比GM10细胞高约1.5倍,并且前一种细胞系对MNU诱导突变的敏感性并未随培养代数而显著变化(即分别在第4代和第16 - 20代时为316×10⁻⁶和326×10⁻⁶突变体/mM MNU)。在所检测的所有传代(4 - 20代)中,GM10细胞系每个细胞含有约75,000个MGMT分子,而GM11细胞系在可获得的最低传代(第4代)时该蛋白质含量不足(约22,500个分子/细胞),并且这种残余活性在第16代时急剧下降至检测不到的水平。总之,这些数据表明,在所检测的两个人胎儿细胞系中,细胞MGMT活性的组成水平与对生殖失活的抗性相关性比对MNU诱导突变的相关性更好,这意味着在至少一些生物系统中,O6meG损伤的低效修复对细胞致死性的影响比对突变诱导的影响更为严重。